Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey

Candel Therapeutics (CADL) drew attention after reporting second quarter 2026 results that showed a net loss of US$38.91 million, compared with US$4.8 million a year earlier, indicating increased operating pressures. See our latest analysis for Candel Therapeutics. The latest earnings release landed alongside sharp share price gains for Candel Therapeutics, with a 1-day share price return of 12.03% and a 90-day share price return of 70.24%. The 3-year total shareholder return is also very...